Erasca, Inc. 8-K

What Happened

• Erasca, Inc. filed an 8‑K on January 12, 2026 to update its corporate presentation (Exhibit 99.1) and disclosed clinical progress for its RAS‑targeting programs. The company reported early responses in the AURORAS‑1 Phase 1 trial of ERAS‑0015 and continued dose escalation in the BOREALIS‑1 Phase 1 trial of ERAS‑4001. The updated presentation will be posted on Erasca’s website and used at the J.P. Morgan Healthcare Conference on January 13, 2026.
• Data cutoff for the clinical update was January 7, 2026. Erasca cautioned that these are preliminary, forward‑looking results.

Key Details

• AURORAS‑1 (ERAS‑0015): two confirmed partial responses (PRs) and one unconfirmed PR observed at a low dose of 8 mg QD; additional unconfirmed responses seen at doses >8 mg. No dose‑limiting toxicities (DLTs) reported to date; safety largely low‑grade. Linear pharmacokinetics observed across dose levels.
• ERAS‑0015 milestones: initial Phase 1 monotherapy data planned for H1 2026; monotherapy expansion and combination dose‑escalation starts planned for H2 2026; expansion and combination data planned for 2027.
• BOREALIS‑1 (ERAS‑4001): dose escalation progressing as expected. Initial Phase 1 monotherapy data planned for H2 2026; monotherapy expansion and combination dose escalation planned for 2027.
• Corporate presentation: updated January 2026 deck attached as Exhibit 99.1; Erasca will post updates on its website and does not intend to file an 8‑K each time the deck is revised.

Why It Matters

• For investors, these are early signs of clinical activity in Erasca’s RAS‑targeting programs and a timeline for near‑term readouts (H1–H2 2026) that could be material catalysts. Reported responses at a low dose and the absence of DLTs are potentially positive safety/efficacy signals, but remain preliminary and based on a small number of patients.
• The company’s note that future presentation updates will be posted online (without separate 8‑Ks) is important for how investors should monitor ongoing program updates. As the filing states, these are forward‑looking and subject to change as more patients are enrolled and data mature.